Vitamin D3 analogs for the treatment of osteoporosis1

Canadian Journal of Physiology and Pharmacology

Volumn 93, Issue 5, 2015, Pages 327-332

  Hagino, Hiroshi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

2MD; Eldecalcitol; Mini modeling; Vitamin D receptor ligand; Vitamin D binding protein

Indexed keywords

CALCITRIOL; COLECALCIFEROL; ELDECALCITOL; VITAMIN D;

BODY MASS; BONE STRENGTH; BONE TURNOVER; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; LUMBAR SPINE; MORPHOMETRICS; OSTEOPOROSIS; PLASMA HALF LIFE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; METABOLISM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANIMALS; CHOLECALCIFEROL; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAMIN D;

EID: 84928896517     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0419     Document Type: Review

References (33)

1. Abe, M., Tsuji, N., Takahashi, F., and Tanigawara, Y. 2011. Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative. Jpn. Pharmacol. Ther. 39: 261-274
2. Barycki, R., Sicinski, R.R., Plum, L.A., Grzywacz, P., Clagett-Dame, M., and Deluca, H.F. 2009. Removal of the 20-methyl group from 2-methylene-19-nor- (20S)-1alpha,25-dihydroxyvitamin D(3) (2MD) selectively eliminates bone calcium mobilization activity. Bioorg. Med. Chem. 17(22): 7658-7669. doi:10.1016/j.bmc.2009.09.047. PMID:19819702
3. Choi, M., and Makishima, M. 2009. Therapeutic applications for novel nonhypercalcemic vitamin D receptor ligands. Expert Opin. Ther. Pat. 19(5): 593-606. doi:10.1517/13543770902877717. PMID:19441936
4. de Freitas, P.H., Hasegawa, T., Takeda, S., Sasaki, M., Tabata, C., Oda, K., et al. 2011. Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone, 49(3): 335-342. doi:10.1016/j.bone.2011.05.022. PMID:21664310
5. DeLuca, H.F., Bedale, W., Binkley, N., Gallagher, J.C., Bolognese, M., Peacock, M., et al. 2011. The vitamin D analogue 2MD increases bone turnover but notBMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial. J. Bone Miner. Res. 26(3): 538-545. doi:10.1002/jbmr.256. PMID:20890933
6. Erben, R.G., Mosekilde, L., Thomsen, J.S., Weber, K., Stahr, K., Leyshon, A., et al. 2002. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3. J. Bone Miner. Res. 17(8): 1498-1511. doi:10.1359/jbmr.2002.17.8.1498. PMID:12162504
7. Furuichi, T., Kawata, S., Asoh, Y., Kumaki, K., and Ohyama, Y. 1998. Differential time course of induction of 1a,25-dihydroxyvitamin D3-24-hydroxylase mRNA expression in rats by 1a,25-dihydroxyvitamin D3 and its analogs. Life Sci. 62(5): 453-459. doi:10.1016/S0024-3205(97)01139-9. PMID:9449236
8. Harada, S., Takeda, S., Uno, A., Takahashi, F., and Saito, H. 2010. Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo. J. Steroid Biochem. Mol. Biol. 121(1-2): 281-283. doi:10.1016/j.jsbmb.2010.04.001. PMID:20398764
9. Harada, S., Mizoguchi, T., Kobayashi, Y., Nakamichi, Y., Takeda, S., Sakai, S., et al. 2012. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J. Bone Miner. Res. 27(2): 461-473. doi:10.1002/jbmr.555. PMID:22052469
10. Hatakeyama, S., Nagashima, S., Imai, N., Takahashi, K., Ishihara, J., Sugita, A., et al. 2007. Synthesis and biological evaluation of a 3-positon epimer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71). J. Steroid Biochem. Mol. Biol. 103(3-5): 222-226. doi:10.1016/j.jsbmb.2006.12.025. PMID: 17207991
11. Ishii, M., Egen, J.G., Klauschen, F., Meier-Schellersheim, M., Saeki, Y., Vacher, J., et al. 2009. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature, 458(7237): 524-528. doi:10.1038/nature07713. PMID:19204730
12. Ke, H.Z., Qi, H., Crawford, D.T., Simmons, H.A., Xu, G., Li, M., et al. 2005. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J. Bone Miner. Res. 20(10): 1742-1755. doi:10.1359/JBMR.050605. PMID:16160732
13. Kikuta, J., Kawamura, S., Okiji, F., Shirazaki, M., Sakai, S., Saito, H., and Ishii, M. 2013. Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc. Natl. Acad. Sci. U.S.A. 110(17): 7009-7013. doi:10.1073/pnas.1218799110. PMID:23569273
14. Matsumoto, T., and Kubodera, N. 2007. ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J. Steroid Biochem. Mol. Biol. 103(3-5): 584-586. doi:10.1016/j.jsbmb.2006.12.088. PMID:17298881
15. Matsumoto, T., Miki, T., Hagino, H., Sugimoto, T., Okamoto, S., Hirota, T., et al. 2005. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 90(9): 5031-5036. doi:10.1210/jc.2004-2552. PMID:15972580
16. Matsumoto, T., Takano, T., Yamakido, S., Takahashi, F., and Tsuji, N. 2010. Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J. Steroid Biochem. Mol. Biol. 121(1-2): 261-264. doi:10.1016/j.jsbmb.2010.03.035. PMID:20298784
17. Matsumoto, T., Ito, M., Hayashi, Y., Hirota, T., Tanigawara, Y., Sone, T., et al. 2011. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-a randomized, active comparator, double-blind study. Bone, 49(4): 605-612. doi:10.1016/j.bone.2011.07.011. PMID:21784190
18. Miyamoto, K., Murayama, E., Ochi, K., Watanabe, H., and Kubodera, N. 1993. Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2 beta-position. Chem. Pharm. Bull. 41(6): 1111-1113. doi:10.1248/cpb.41.1111. PMID:8396500
19. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. 2001. Osteoporosis prevention, diagnosis, and therapy. JAMA, 285(6): 785-795. doi:10.1001/jama.285.6.785. PMID:11176917
20. Okano, T., Tsugawa, N., Masuda, S., Takeuchi, A., Kobayashi, T., Takita, Y., and Nishii, Y. 1989. Regulatory activities of 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem. Biophys. Res. Commun. 163(3): 1444-1449. doi:10.1016/0006-291X(89)91140-6. PMID:2551289
21. Papadimitropoulos, E., Wells, G., Shea, B., Gillespie, W., Weaver, B., Zytaruk, N., et al; The Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr. Rev. 23(4): 560-569. doi:10.1210/er.2001-8002. PMID:12202471
22. Ritter, C.S., and Brown, A.J. 2011. Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D-binding protein and resistance to metabolism. J. Cell. Biochem. 112(5): 1348-1352. doi:10.1002/jcb.23051. PMID:21337382
23. Saito, H., and Harada, S. 2014. Eldecalcitol replaces endogenous calcitriol but does not fully compensate for its action in vivo. J. Steroid Biochem. Mol. Biol. 144(Pt. A): 189-196. doi:10.1016/j.jsbmb.2013.11.013. PMID:24291401
24. Sakai, S., Takaishi, H., Matsuzaki, K., Kaneko, H., Furukawa, M., Miyauchi, Y., et al. 2009. 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J. Bone Miner. Metab. 27(6): 643-652. doi:10.1007/s00774-009-0084-4. PMID:19449179
25. Sicinski, R.R., Prahl, J.M., Smith, C.M., and DeLuca, H.F. 1998. New 1alpha,25- dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J. Med. Chem. 41(23): 4662-4674. doi:10.1021/jm9802618. PMID: 9804706
26. Takasu, H., Sugita, A., Uchiyama, Y., Katagiri, N., Okazaki, M., Ogata, E., and Ikeda, K. 2006. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J. Clin. Invest. 116(2): 528-535. doi:10.1172/JCI24742. PMID:16424941
27. Tsurukami, H., Nakamura, T., Suzuki, K., Sato, K., Higuchi, Y., and Nishii, Y. 1994. A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif. Tissue Int. 54(2): 142-149. doi:10.1007/BF00296065. PMID:8012869
28. Uchiyama, Y., Higuch, I.Y., Takeda, S., Masaki, T., Shira-Ishi, A., Sato, K., et al. 2002. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone, 30(4): 582-588. doi:10.1016/S8756-3282(02)00682-8. PMID:11934649
29. Ueno, Y., Shinki, T., Nagai, Y., Murayama, H., Fujii, K., and Suda, T. 2003. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J. Cell. Biochem. 90(2): 267-277. doi:10.1002/jcb.10623. PMID: 14505343
30. Vanhooke, J.L., Tadi, B.P., Benning, M.M., Plum, L.A., and DeLuca, H.F. 2007. New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains: evaluation of biological activity and structural determination of VDR-bound conformations. Arch. Biochem. Biophys. 460(2): 161-165. doi:10.1016/j.abb.2006.11.029. PMID:17227670
31. Yamamoto, Y., Yoshizawa, T., Fukuda, T., Shirode-Fukuda, Y., Yu, T., Sekine, K., et al. 2013. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology, 154(3): 1008-1020. doi:10.1210/en.2012-1542. PMID:23389957
32. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 95(7): 3597-3602. doi:10.1073/pnas.95.7.3597. PMID: 9520411
33. Zella, J.B., Plum, L.A., Plowchalk, D.R., Potochoiba, M., Clagett-Dame, M., and DeLuca, H.F. 2014. Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. Am. J. Nephrol. 39(6): 476-483. doi:10.1159/000362846. PMID:24854296